查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790476

美国抗病毒药物市场规模、份额和趋势分析报告：按类型、药物类别、分销管道和细分市场预测，2025-2030 年

U.S. Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Drug Class, By Distribution Channel (Hospital, Retail, Online) And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 60 Pages | 商品交期: 2-10个工作天内

价格

美国抗病毒药物市场摘要

美国抗病毒药物市场规模预计在 2024 年为 264.1 亿美元，预计在 2030 年将达到 236.1 亿美元，2025 年至 2030 年的复合年增长率为 -1%。这一下降主要是由于针对 COVID-19的抗病毒药物需求下降，以及 2025 年重症患者和相关住院人数大幅下降。

美国抗病毒药物市场主要驱动力是爱滋病毒、B型肝炎和C肝、疱疹和流感的治疗。美国疾病管制与预防中心 (CDC) 估计，美国约有 12 亿人感染爱滋病毒，24 亿人感染C肝，85 万人感染B型肝炎。 CDC 的一份报告显示，截至 2025 年中期，包括流感、新冠肺炎 (COVID-19) 和呼吸道合胞病毒 (RSV) 在内的急性呼吸道疾病在美国仍处于非常低的水平，这减少了对抗病毒药物的迫切需求。低发病率，加上用于缓解症状和增强免疫力的补充疗法的使用日益增多，正在抑制抗病毒药物市场的成长。

例如，C型肝炎药物Sovaldi每片售价约1,000美元，12週治疗总费用约8.4万美元。同样，Orysio每月售价为2.36万美元，预计治疗时间最长为48週。

美国食品药物管理局(FDA) 的法律规范在塑造抗病毒产业方面发挥着至关重要的作用。 FDA 严格的核准流程确保了其安全性和有效性，近期的核准重点关注联合治疗和儿科适应症。 2025 年 6 月，FDA核准扩大 MAVYRET 的用途，用于治疗 3 岁及以上儿童的急性C型肝炎。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国抗病毒药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国抗病毒药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 美国抗病毒市场：产品线分析

第四章：美国抗病毒药物市场：按类型估计和趋势分析

  • 类型细分仪表板
  • 美国抗病毒药物市场：按类型变化分析
  • 美国抗病毒药物市场规模及趋势分析（2018-2030）
  • 品牌
  • 学名药

第五章美国抗病毒药物市场：药物类别估计与趋势分析

  • 药品类别细分仪表板
  • 美国抗病毒药物市场：药物类别变化分析
  • 美国抗病毒药物市场规模及趋势分析（依药物类别，2018-2030年）
  • DNA聚合酵素抑制剂
  • 逆转录酶抑制剂
  • 蛋白酶抑制剂
  • 神经氨酸酶抑制剂
  • 其他的

第六章：美国抗病毒药物市场：应用估计与趋势分析

  • 应用程式细分仪表板
  • 美国抗病毒药物市场：应用波动分析
  • 美国抗病毒药物市场规模及趋势分析（按应用，2018-2030）
  • HIV
  • 肝炎
  • 疱疹
  • 流感
  • 其他的

第七章：美国抗病毒药物市场：通路评估与趋势分析

  • 分销通路细分仪表板
  • 美国抗病毒药物市场：分销管道波动分析
  • 美国抗病毒药物市场规模及趋势分析（按分销管道，2018-2030年）
  • 医院药房
  • 零售药局
  • 网路药局

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key company heat map analysis, 2024
  • 公司简介
    • F. Hoffmann-La Roche Ltd.
    • GSK plc.
    • AbbVie, Inc.
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • Cipla Inc.
    • Aurobindo Pharma
    • Dr. Reddy's Laboratories Ltd.
    • ADARx Pharmaceuticals Inc.
Product Code: GVR-4-68040-665-5

U.S. Antiviral Drugs Market Summary

The U.S. antiviral drugs market size was estimated at USD 26.41 billion in 2024 and is projected to reach USD 23.61 billion by 2030, growing at a CAGR of -1% from 2025 to 2030. This decline is largely due to the waning demand for COVID-19-specific antivirals, as the number of severe COVID-19 cases and related hospitalizations has dropped significantly in 2025.

Treatments for HIV, hepatitis B and C, herpes, and influenza primarily drive the U.S. market for antiviral drugs. The CDC estimates that about 1.2 billion people in the U.S. are living with HIV, 2.4 billion with hepatitis C, and 850,000 with hepatitis B. The CDC reports that acute respiratory illnesses, including influenza, COVID-19, and RSV, remain at very low levels in the U.S. as of mid-2025, reducing the immediate demand for antiviral medications. This low incidence, combined with the growing use of complementary health approaches for symptom relief and immune support, has moderated the growth of the antiviral drugs market.

Despite these advancements, the high cost of antiviral treatments remains a significant challenge for many patients and healthcare systems in the U.S. For instance, the hepatitis C drug Sovaldi costs approximately USD 1,000 per pill, resulting in a total treatment cost of around USD 84,000 for a 12-week course . Similarly, Olysio's monthly treatment cost is estimated at USD 23,600, with treatment durations extending up to 48 weeks.

Regulatory oversight by the U.S. Food and Drug Administration (FDA) plays an essential role in shaping the antiviral drugs industry. The FDA's rigorous approval process ensures safety and efficacy, with recent approvals emphasizing combination therapies and pediatric indications. In June 2025, the FDA approved the expanded use of Mavyret for acute hepatitis C in children aged 3 and above.

U.S. Antiviral Drugs Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global U.S. antiviral drugs industry report based on type, drug class, application, and distribution channel.

  • Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Branded
  • Generics
  • Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others
  • Application Outlook (Revenue, USD Billion, 2018 - 2030)
  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Application
    • 1.2.4. Distribution Channel
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type
    • 2.2.2. Drug Class
    • 2.2.3. Application
    • 2.2.4. Distribution Channel
  • 2.3. Competitive Insights

Chapter 3. U.S. Antiviral Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Antiviral Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. U.S. Antiviral Drugs Market: Pipeline Analysis

Chapter 4. U.S. Antiviral Drugs Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. U.S. Antiviral Drugs Market: Type Movement Analysis
  • 4.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 4.4. Branded
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Generics
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Antiviral Drugs Market: Drug Class Estimates & Trend Analysis

  • 5.1. Drug Class Segment Dashboard
  • 5.2. U.S. Antiviral Drugs Market: Drug Class Movement Analysis
  • 5.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Billion)
  • 5.4. DNA Polymerase Inhibitors
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Reverse Transcriptase Inhibitors
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Protease Inhibitors
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Neuraminidase Inhibitors
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.8. Others
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Antiviral Drugs Market: Application Estimates & Trend Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. U.S. Antiviral Drugs Market: Application Movement Analysis
  • 6.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Billion)
  • 6.4. HIV
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Hepatitis
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Herpes
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Influenza
    • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8. Others
    • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. U.S. Antiviral Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Segment Dashboard
  • 7.2. U.S. Antiviral Drugs Market: Distribution Channel Movement Analysis
  • 7.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
  • 7.4. Hospital Pharmacy
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5. Retail Pharmacy
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6. Online Pharmacy
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. GSK plc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. AbbVie, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Merck & Co., Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Johnson & Johnson Services, Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Bristol-Myers Squibb Company
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Cipla Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Aurobindo Pharma
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Dr. Reddy's Laboratories Ltd.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. ADARx Pharmaceuticals Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. Antiviral Drugs Market 2018 - 2030 (USD Billion)
  • Table 3 U.S. Antiviral Drugs Market, by Type, 2018 - 2030 (USD Billion)
  • Table 4 U.S. Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Antiviral Drugs Market, by Application, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Information Procurement
  • Fig. 7 Market Formulation and Validation
  • Fig. 8 Data Validating & Publishing
  • Fig. 9 Market Segmentation & Scope
  • Fig. 10 U.S. Antiviral Drugs Market Snapshot
  • Fig. 11 Type Segment Snapshot
  • Fig. 12 Drug Class Segment Snapshot
  • Fig. 13 Application Segment Snapshot
  • Fig. 14 Distribution Channel Segment Snapshot
  • Fig. 15 Competitive Landscape Snapshot
  • Fig. 16 Parent market outlook
  • Fig. 17 U.S. Antiviral Drugs Market Value, 2024 (USD Billion)
  • Fig. 18 U.S. Antiviral Drugs Market - Value Chain Analysis
  • Fig. 19 U.S. Antiviral Drugs Market - Market Dynamics
  • Fig. 20 U.S. Antiviral Drugs Market - PORTER's Analysis
  • Fig. 21 U.S. Antiviral Drugs Market - PESTEL Analysis
  • Fig. 22 U.S. Antiviral Drugs Market Estimates & Forecasts, By Type: Key Takeaways
  • Fig. 23 U.S. Antiviral Drugs Market Share, By Type, 2024 & 2030
  • Fig. 24 Branded Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Generics Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 U.S. Antiviral Drugs Market Estimates & Forecasts, By Drug Class: Key Takeaways
  • Fig. 27 U.S. Antiviral Drugs Market Share, By Drug Class, 2024 & 2030
  • Fig. 28 DNA Polymerase Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 Reverse Transcriptase Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Protease Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Neuraminidase Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 Other Drug Class Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 U.S. Antiviral Drugs Market Estimates & Forecasts, By Application: Key Takeaways
  • Fig. 34 U.S. Antiviral Drugs Market Share, By Application, 2024 & 2030
  • Fig. 35 HIV Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Hepatitis Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 Herpes Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Influenza Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Other Applications Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 U.S. Antiviral Drugs Market Estimates & Forecasts, By Distribution Channel: Key Takeaways
  • Fig. 41 U.S. Antiviral Drugs Market Share, By Distribution Channel, 2024 & 2030
  • Fig. 42 Hospital Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 Retail Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Online Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Key Company Categorization
  • Fig. 46 Company Market Positioning
  • Fig. 47 Strategy Mapping